BioPharma Resources

Drug Trial Radar · NCT06325930

A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

An Open-Label Phase 1 Study in Healthy Adult Male Subjects to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6 Following Single-Dose Oral Administration

Last checked: Nov 19, 2026Latest source record: May 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Mar 26, 2024

Primary completion

May 7, 2024

Study completion May 7, 2024

Sponsor

Lead sponsor
Rivus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, non-randomized, open-label Phase 1 study to characterize the absorption, metabolism, excretion, mass balance, pharmacokinetics (PK), safety and tolerability of HU6 following administration of a single dose of \[14C\]-HU6 in a fed state with a standard meal administered approximately 15 minutes prior to dosing.

Conditions

  • Healthy

Interventions

  • [14C]-HU6Drug

    \[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the mass balanceTime frame: Up to Day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron Clinical Pharmacology Center (CPC)

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.